Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).

ABSTRACT:

Introduction

Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. Fibrotic diseases such as these can be mediated by lysophosphatidic acid (LPA), which signals via six LPA receptors (LPA_1-6). Signalling via LPA₁ appears to be fundamental in the pathogenesis of fibrotic diseases. BMS-986278, a second-generation LPA₁ antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD.

Methods and analysis

This phase 2, randomised, double-blind, placebo-contro

SUBMITTER: Corte TJ 

PROVIDER: S-EPMC8718498 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature